Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial.

Abstract

INTRODUCTION/OBJECTIVE Long-term use of the atypical antipsychotic iloperidone has not been investigated at doses above 16 mg/d. This article describes safety and tolerability results from the 25-week open-label extension of a 4-week placebo- and ziprasidone-controlled clinical trial of iloperidone. METHODS Patients received a dose of 24 mg/d (given as 12… (More)
DOI: 10.1017/S1092852912000764

Topics

  • Presentations referencing similar topics